Acotec Scientific Holdings Limited (6669) AI Stock Analysis

• Market Cap: €3.88B
• Dividend Yield: N/A
• Average Volume (3M): 878.26K
• Price to Earnings (P/E): 34.3
• Beta (1Y): 1.01
• Revenue Growth: 12.94%
• EPS Growth: 212.66%
• Country: HK
• Employees: 650
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Devices
• EPS (TTM): 0.32
• Shares Outstanding: 313,389,160
• 10 Day Avg. Volume: 757,452
• 30 Day Avg. Volume: 878,265
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €16.97
• Price Target Upside: 34.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: HK$17.00 ▲(34.92% Upside)

Acotec Scientific Holdings benefits from strong technical momentum and a robust balance sheet, which are significant positives. However, high valuation and challenges in profitability and cash flow management present risks. Investors should be cautious of potential overvaluation and focus on the company's ability to improve operational efficiency.

Acotec Scientific Holdings Limited Business Overview & Revenue Model

Company Description

Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.

How the Company Makes Money

Acotec Scientific Holdings Limited generates revenue through the sale of its medical devices to hospitals, healthcare institutions, and distributors. The company focuses on producing high-quality interventional medical products, which are used in various medical procedures. Revenue streams are primarily derived from the domestic market in China, with an expanding presence in international markets. Significant partnerships with healthcare providers and ongoing research and development efforts contribute to the company's earnings by continuously enhancing its product offerings and ensuring compliance with regulatory standards.

Acotec Scientific Holdings Limited Financial Statement Overview

Summary

Acotec Scientific Holdings shows strong revenue growth and a healthy balance sheet with low leverage. However, the company faces challenges with profitability margins and cash flow trends, indicating areas for improvement in operational efficiency and cash flow stabilization.

Income Statement

Acotec Scientific Holdings has demonstrated solid revenue growth, with a notable increase from the previous year, indicating a positive growth trajectory. The gross profit margin remains robust, reflecting strong operational efficiency. However, the net profit margin and EBIT margin are relatively constrained, suggesting room for improvement in cost management and operational leverage.

Balance Sheet

The company's balance sheet is healthy, with a strong equity position and a low debt-to-equity ratio, highlighting financial stability and low leverage risk. The equity ratio is high, indicating effective asset management. However, there is limited information on return on equity due to inconsistent net income figures in previous years.

Cash Flow

Acotec Scientific Holdings' cash flow statement indicates challenges, with operating and free cash flows showing negative trends in recent years. However, the company managed to improve its cash position significantly. The lack of available data on free cash flow growth rates limits further analysis.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	523.12M	533.99M	473.85M	395.55M	303.81M	193.97M
Gross Profit	399.51M	402.72M	377.42M	336.35M	265.94M	163.78M
EBITDA	35.01M	112.48M	70.54M	91.17M	-51.02M	-24.66M
Net Income	32.08M	52.28M	14.49M	70.14M	-79.08M	-44.29M
Balance Sheet
Total Assets	1.71B	1.66B	1.61B	1.41B	1.31B	272.94M
Cash, Cash Equivalents and Short-Term Investments	927.21M	809.57M	879.21M	986.46M	1.14B	147.10M
Total Debt	259.67M	202.92M	234.00M	47.78M	24.57M	41.41M
Total Liabilities	371.93M	312.76M	314.53M	134.46M	100.17M	553.95M
Stockholders Equity	1.34B	1.35B	1.30B	1.28B	1.21B	-281.01M
Cash Flow
Free Cash Flow	-54.90M	5.31M	-92.54M	-115.45M	-31.72M	-27.39M
Operating Cash Flow	27.34M	102.79M	-12.88M	-68.75M	-10.48M	-8.77M
Investing Cash Flow	-300.33M	45.02M	-319.22M	-49.17M	-20.48M	-17.73M
Financing Cash Flow	17.53M	-35.24M	-23.21M	-32.87M	1.02B	142.52M

Acotec Scientific Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6669, the sentiment is Neutral. The current price of 12.6 is below the 20-day moving average (MA) of 13.51, below the 50-day MA of 12.72, and above the 200-day MA of 8.75, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 46.37 is Neutral, neither overbought nor oversold. The STOCH value of 9.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6669.

Acotec Scientific Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6669	72 Outperform	€3.88B	34.31	7.44%	―	12.94%	212.66%
6609	64 Neutral	HK$2.47B	52.96	-1.28%	―	32.93%	―
2160	51 Neutral	HK$2.99B	563.64	-2.26%	―	-4.38%	―
2500	50 Neutral	HK$1.42B	-2.02	-32.31%	―	-8.56%	-14.84%
9996	41 Neutral	HK$4.10B	-16.75	-11.17%	―	29.25%	9.02%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

Acotec Scientific Holdings Limited Corporate Events

Acotec Scientific Reports Strong Interim Financial Results for 2025

Acotec Scientific Holdings Limited has announced its interim results for the six months ended June 30, 2025, reporting a significant increase in financial performance. The company achieved a 20.1% increase in revenue to RMB 351,204,000 and a 124.1% rise in profit before tax to RMB 89,493,000 compared to the same period in 2024. This growth reflects the company’s strong operational performance and strategic positioning in the market, potentially enhancing its attractiveness to stakeholders and investors.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Scientific Gains Approval for Innovative Medical Device

Acotec Scientific Holdings Limited announced that it has received approval from the PRC National Medical Products Administration for its new Peripheral Controlled Mechanically Detachable Fibered Coil. This product is designed for the embolization of peripheral vascular aneurysms and other conditions, offering a controlled detachment mechanism for improved safety and precision. The approval marks a significant step in the company’s product development, potentially enhancing its market position in the PRC, although the company cautions that successful marketing is not guaranteed.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

Acotec Scientific Gains Approval for Micro Guidewire in China

Acotec Scientific Holdings Limited announced that it has received registration approval from the Beijing Municipal Medical Products Administration for its Micro Guidewire, designed for peripheral vascular procedures. This product, featuring advanced design elements for improved deliverability and torque control, is set to be marketed in the PRC market, potentially enhancing the company’s positioning in the medical device industry.

Acotec Scientific Holdings to Review Interim Results and Dividend

Acotec Scientific Holdings Limited has announced a board meeting scheduled for August 26, 2025, to review and approve the company’s unaudited interim results for the first half of the year and to consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and investor confidence.

Acotec Scientific Gains Approval for New Coronary Treatment Device in China

Acotec Scientific Holdings Limited has announced the approval of its Sirolimus-Coated Coronary Balloon Dilatation Catheter, AcoArt Canna®, by the PRC National Medical Products Administration. This device is designed for treating de novo coronary artery bifurcation lesions and has shown efficacy and safety in clinical trials. The company plans to initiate marketing activities in the Chinese market, although there is no guarantee of successful commercialization.

Acotec Scientific Holdings Limited Successfully Concludes AGM with All Resolutions Passed

Acotec Scientific Holdings Limited announced that all resolutions proposed at its Annual General Meeting (AGM) held on June 30, 2025, were successfully passed by shareholders through a poll. The resolutions included the adoption of the company’s audited financial statements for 2024, the re-election of certain directors, and the re-appointment of KPMG as auditors. This successful AGM indicates strong shareholder support and stability in the company’s governance, potentially reinforcing its market position and stakeholder confidence.

Acotec Scientific Holdings Limited Establishes Nomination Committee

Acotec Scientific Holdings Limited has outlined the terms of reference for its Nomination Committee, established to identify and recommend suitable candidates for the company’s board of directors. The committee, consisting mainly of independent non-executive directors, will ensure the selection process aligns with applicable laws and regulations, potentially impacting the company’s governance and strategic direction.

Acotec Scientific Gains Approval for New High-Pressure Balloon Catheter

Acotec Scientific Holdings Limited has received approval from the PRC National Medical Products Administration for its Peripheral High-pressure Balloon Dilation Catheter, Armoni-HP®. This product is designed for use in percutaneous transluminal angioplasty in peripheral blood vessels and post-stent dilation, offering a high-strength fiber-composite design to ensure optimal clinical performance. The approval marks a significant step in the company’s product development, potentially enhancing its market position in the PRC healthcare sector.